Alkem Laboratories logo

Alkem Laboratories financials and balance sheet

NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap

Last close ₹4,947.00down ₹66.50 (1.33%)BSE ₹4,919.95

Share price at the NSE close on 23 Oct 2026. Previous close ₹5,013.50.

52-week range of traded prices to 23 Oct 2026
₹4,811.00Low, 22 Oct 2026₹5,933.50High, 13 Jan 2026
Market cap
₹59,149 Cr164th largest listed
P/E
27.4
P/B
4.3
Dividend yield
1.07%
ROE
16.7%
ROCE
16.5%
Debt to equity
0.11
Volume, NSE
54,98251.0% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Alkem Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹14,712 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.2% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue14,712
  2. Materials and goods−5,093
  3. Employee costs−2,837
  4. Other expenses−3,777
  5. Operating profit3,005
  6. Depreciation−382
  7. Other income+583
  8. One-off items−175
  9. Finance costs−161
  10. Profit before tax2,871
  11. Tax−518
  12. Joint ventures−2.0
  13. Net profit2,351

What the company owns

  • Plant, investments and other assets₹12,090 Cr
  • Inventory₹3,333 Cr
  • Receivables₹2,979 Cr
  • Cash and bank₹1,733 Cr
  • Current investments₹737 Cr

What pays for it: net worth and liabilities

  • Net worth₹14,349 Cr
  • Other liabilities₹2,656 Cr
  • Owed to suppliers₹2,244 Cr
  • Borrowings₹1,624 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Alkem Laboratories quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 5 JunMar 2021Filed 26 MayMar 2022Filed 14 MayMar 2023Filed 22 MayMar 2024Filed 1 JunMar 2025Filed 27 JunMar 2026Filed 28 May
Revenue from operations5,8536,4317,3578,3448,86510,63411,59912,66812,96514,712
4,8545,4036,2426,8716,9238,5819,99010,42210,45211,707
Materials and goods bought2,2222,5132,9453,3453,4984,1804,9074,9384,7645,093
Employee costs1,0041,1921,3621,5051,6211,9632,1312,2012,4542,837
Other expenses1,6281,6981,9352,0211,8032,4382,9523,2843,2343,777
Operating profit before depreciation9991,0281,1151,4731,9422,0531,6092,2452,5123,005
Operating margin17.1%16.0%15.2%17.7%21.9%19.3%13.9%17.7%19.4%20.4%
Materials, % of revenue38.0%39.1%40.0%40.1%39.5%39.3%42.3%39.0%36.7%34.6%
Employee costs, % of revenue17.2%18.5%18.5%18.0%18.3%18.5%18.4%17.4%18.9%19.3%
Other expenses, % of revenue27.8%26.4%26.3%24.2%20.3%22.9%25.4%25.9%24.9%25.7%
Depreciation and amortisation101143193253275304310299357382
Operating profit after depreciation8988859221,2211,6681,7491,2991,9462,1552,623
Other income1129688104233163216311494583
Finance costs455555655952107112122161
Profit before one-off items and tax9659269551,2601,8421,8591,4082,1452,5273,046
One-off items00000−15−103−1210−175
Profit before tax9659269551,2601,8421,8441,3052,0232,5272,871
60288181110224164298212311518
Share of profit of joint ventures and associates––––––––−1−2
9056387741,1491,6181,6801,0071,8112,2152,351
Other comprehensive income––3127−34341152020184
Total comprehensive income––8051,1761,5831,7141,1221,8322,2352,535
Net margin15.5%9.9%10.5%13.8%18.2%15.8%8.7%14.3%17.1%16.0%
Net margin without joint ventures and associates––––––––17.1%16.0%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 30 MayMar 2020Filed 5 JunMar 2021Filed 26 MayMar 2022Filed 14 MayMar 2023Filed 22 MayMar 2024Filed 1 JunMar 2025Filed 27 JunMar 2026Filed 28 May
5,5726,3097,5588,8479,43510,71412,43414,349
5,4396,1617,3778,6389,04510,31211,98513,820
Share capital2424242424242424
Reserves5,4156,1377,3538,6149,02110,28811,96113,796
Belonging to outside owners of subsidiaries133148181209390402449529
9031,6631,6702,6681,3971,2141,0631,624
2,1903,2433,6044,8053,7073,9953,9594,783
4463913574176158661,2921,741
Liabilities going with businesses held for sale––––––6–
8,2089,94311,51914,06913,75715,57517,69120,873
3,9924,4474,5905,6345,0275,1636,7458,662
4,2165,4786,9238,4348,60610,41210,81112,211
Net debt13401−499−50−1,537−514−1,403−847
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 26 MayMar 2022Filed 14 MayMar 2023Filed 22 MayMar 2024Filed 1 JunMar 2025Filed 27 JunMar 2026Filed 28 May
1,2651,1111,6831,9481,9131,963
1,6661,5081,9562,3552,4172,592
−341−545327−52−214−415
Receivables−26−222−135−222−219−329
Inventories−498−673473−73−261−247
Payables21233415525217121
Other working capital−3015−26−2824940
Tax paid−401−397−273−407−504−629
Capital spending195339233259676617
Free cash flow1,0707721,4501,6891,2371,346
−999−1,435113−1,009−1,299−1,667
−272380−1,761−1,145−811−503
Dividends paid335422530540505614
Shares bought back000000
Shares issued00161000
Net change in cash−55535−205−197−208
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Alkem Laboratories dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 5 JunMar 2021Filed 26 MayMar 2022Filed 14 MayMar 2023Filed 22 MayMar 2024Filed 1 JunMar 2025Filed 27 JunMar 2026Filed 28 May
Earnings per share₹74.61₹52.77₹63.61₹94.26₹132.57₹137.63₹82.31₹150.19₹181.11₹192.51
Diluted earnings per share₹74.61₹52.77₹63.61₹94.26₹132.57₹137.63₹82.31₹150.19₹181.11₹192.51
Dividend per share₹15.00₹13.00₹16.00₹25.00₹30.00₹34.00₹50.00₹40.00₹45.00₹53.00
Book value per share––₹454.98₹515.32₹617.04₹722.53₹756.61₹862.57₹1,002.50₹1,156.01
Dividend payout19.8%24.3%25.2%26.5%22.6%24.7%60.7%26.6%24.8%27.5%
Shareholder yield––––1.0%1.0%0.9%0.9%0.9%1.0%
Market cap at the year end (₹ crore)26,36323,77420,93427,80933,11743,29140,60559,08958,36863,357

Ratios

Consolidated, years to March.Alkem Laboratories PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 5 JunMar 2021Filed 26 MayMar 2022Filed 14 MayMar 2023Filed 22 MayMar 2024Filed 1 JunMar 2025Filed 27 JunMar 2026Filed 28 May
Revenue growth17.2%9.9%14.4%13.4%6.2%20.0%9.1%9.2%2.3%13.5%
Operating profit growth17.8%2.9%8.4%32.2%31.8%5.7%−21.6%39.5%11.9%19.6%
Net profit growth34.4%−29.4%21.2%48.6%40.8%3.9%−40.1%79.9%22.3%6.1%
Earnings per share growth–−29.3%20.5%48.2%40.6%3.8%−40.2%82.5%20.6%6.3%
––14.0%19.4%23.4%20.6%11.1%18.6%19.4%17.8%
–––5.5 pts4.0 pts−2.9 pts−9.4 pts7.4 pts0.9 pts−1.6 pts
From the net margin–––4.3 pts6.3 pts−3.1 pts−9.3 pts7.5 pts3.3 pts−1.2 pts
From asset turnover–––0.5 pts−2.6 pts0.1 pts0.0 pts0.7 pts−2.1 pts−0.4 pts
From borrowing–––0.7 pts0.3 pts0.2 pts−0.2 pts−0.7 pts−0.3 pts0.0 pts
Return on capital employed––14.2%15.3%18.1%15.2%12.0%16.3%16.0%16.4%
Cash conversion––––78.2%66.1%167.1%107.5%86.3%83.5%
Interest cover19.916.016.918.828.333.412.117.317.716.3
Debt to equity––0.160.260.220.300.150.110.090.11
Receivable days––6272666567656974
Inventory days––186198241262194197224239
Payable days––11910411210287129141161
Cash conversion cycle, days––129167196225174132152152
Working capital days––90108115120104169145151
Asset turnover––0.900.920.830.830.830.860.780.76
Assets per rupee of net worth––1.511.561.591.601.571.521.491.49
Sales per rupee of plant––3.493.623.974.655.625.866.285.46
Capital spending to depreciation––––0.711.110.750.871.891.62
Plant being built, % of plant in use––23.4%15.7%17.6%14.8%15.0%6.9%23.1%5.1%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
11.9%
Cash from operations against operating profit
65.3%
Measure10 years5 years3 years
Revenue growth, yearly rate11.4%10.7%8.2%
Profit growth, yearly rate13.1%7.7%32.7%
Return on equity, average–17.5%18.6%
Return on capital employed, average–15.2%16.2%
Operating margin, average17.8%18.1%19.2%
Net margin, average14.0%14.4%15.8%
Asset turnover, average–0.810.80
Cash conversion cycle, days, average–167146
Interest cover, average19.719.417.1
Debt to equity, average–0.150.10

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations8,6175,8241,963
Cash from investing−5,297−3,974−1,667
Cash from financing−3,841−2,459−503
Capital spending2,1241,552617
Dividends paid2,6101,659614
Shares bought back000
Shares issued for cash16100
Borrowings raised–642314
Borrowings repaid1,0971,06865

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––756964
Altman Z-scorePublished threshold 1.81––7.297.007.577.348.169.989.308.36
Beneish M-scorePublished threshold −1.78––––−2.37−2.14−2.53−2.52−2.19−2.22
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––12.5915.67−5.675.959.6310.66
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.941.051.100.91
Receivables growth less revenue growthOur threshold 0 percentage points–––18.70−8.80−2.704.06−3.557.137.31
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––7.6822.5510.48−30.621.4313.337.16
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.060.940.021.0422.37−6.263.22
Assets under construction, years of additionsOur threshold 2 years of additions–––0.801.940.953.500.381.840.14
Effective tax ratePublished threshold 17.16 per cent6.2231.0518.968.7712.188.8922.8410.4612.3118.03
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−12.631.88−9.65−7.64−3.88
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Jul 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A1+Review, Re-affirm10
8 Jul 2026CRISIL Ratings Limited (opens in a new tab)Commercial PaperCrisil A1+Review, Re-affirm350
8 Jul 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil AA+Review, Re-affirmStable340
6 Feb 2026India Ratings and Research Private Limited (opens in a new tab)Commercial paperIND A1+Review, Re-affirm500
5 Jan 2026CARE Ratings Limited (opens in a new tab)LT/ST Fund-based/Non-fund-based-CC/WCDL/OD/LC/BGCARE AA+ / CARE A1+Review, Re-affirmStable300
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.